PI3K/AKT/JAK2-IN-1
PI3K/AKT/JAK2-IN-1 is a potent multi-target inhibitor of the PI3K/AKT/JAK2 signaling pathway. PI3K/AKT/JAK2-IN-1 suppresses NO production (IC50 = 1.0 μM), reduces pro-inflammatory cytokines (TNF-α, IL-6, IL-1β, IL-17A, IL-22), and inhibits keratinocyte hyperproliferation by downregulating Ki67 and PCNA. PI3K/AKT/JAK2-IN-1 can be used for psoriasis research.
For research use only. We do not sell to patients.
- Formula: C25H14Cl2O7
- Molecular Weight:497.28
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
IC50 & Target
[1]|
IL-1β |
IL-17A |
IL-22 |
IL-6 |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| RAW264.7 | CC50 |
40 μM
|
Exhibits low cytotoxicity toward RAW264.7 cells for 24h.
Exhibits low cytotoxicity toward RAW264.7 cells for 24h.
|
42235429 |
In Vitro
PI3K/AKT/JAK2-IN-1 (compound 15) (5-20 μM; 24 h) exhibits low cytotoxicity toward RAW264.7 cells, with a CC50 > 40 μM [1].
PI3K/AKT/JAK2-IN-1 (5-20 μM; 26 h) shows dose-dependent inhibition of NO production in LPS (HY-D1056)-stimulated RAW264.7 cells, with an IC50 of 1.0 μM [1].
PI3K/AKT/JAK2-IN-1(5-20 μM; 26 h) significantly inhibits the production of TNF-α, IL-6, and IL-1β in LPS-stimulated RAW264.7 cells [1].
PI3K/AKT/JAK2-IN-1 (5-20 μM; 24 h) does not significantly impair HaCaT cell viability [1].
PI3K/AKT/JAK2-IN-1 (5-20 μM; 26 h) significantly reduces the levels of IL-17A and IL-22 in IL-1β-stimulated HaCaT cells [1].
PI3K/AKT/JAK2-IN-1 shows strong binding to PI3K, AKT, JAK2, mTOR, and P62 in molecular docking analysis[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:RAW264.7 cells
-
Concentration:5, 10, or 20 μM
-
Incubation Time:24 h
-
Result:Exhibited low cytotoxicity toward RAW264.7 cells at all tested concentrations, with a CC50 > 40 μM.
-
Cell Line:HaCaT cells
-
Concentration:5, 10, or 20 μM
-
Incubation Time:24 h
-
Result:Did not impair HaCaT cell viability at all tested concentrations.
-
Cell Line:RAW264.7 cells
-
Concentration:5, 10, or 20 μM
-
Incubation Time:24 h
-
Result:Significantly inhibited the production of TNF-α, IL-6, and IL-1β compared to the LPS-induced group at all tested concentrations.
-
Cell Line:IL-1β-stimulated HaCaT cells
-
Concentration:5, 10, or 20 μM
-
Incubation Time:24 h
-
Result:Significantly inhibited the production of IL-17A and IL-22 compared to the IL-1β-induced group at all tested concentrations.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Balb/c mice (male, 6-8 weeks, 20 g), topically administered with 62.5 mg Imiquimod (HY-B0180) on the dorsal skin once daily for 5 days)[1]
-
Dosage:25 mg/kg, 50 mg/kg, 100 mg/kg
-
Administration:Topical application (topical); once daily; 5 days (starting simultaneously with IMQ application)
-
Result:Significantly ameliorated psoriasis-like skin lesions, including reduced erythema, scales, and skin thickness.
Decreased PASI scores compared with the model group.
Reduced the spleen index in a dose-dependent manner, with medium-dose (50 mg/kg) and high-dose (100 mg/kg) groups approaching normal levels.
H&E staining revealed that epidermal hyperplasia and parakeratosis were effectively ameliorated, with the high-dose group showing the most significant improvement.
Immunofluorescence staining showed that Ki67 and PCNA expression levels in dorsal skin were markedly reduced.
Significantly decreased the levels of IL-17A, IL-23, IL-1β, and IFN-γ in both skin lesions and serum.
Western blot analysis demonstrated that PI3K, AKT, and JAK2 protein expressions in dorsal skin were downregulated.
Chemical Information
-
Molecular Weight 497.28
-
Formula C25H14Cl2O7
-
SMILES
O=C1OC2=CC=CC=C2C(O)=C1C(C3=C(C4=C(OC3=O)C=CC=C4)O)C5=CC(Cl)=CC(Cl)=C5O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Ki-67 Immunostaining Proliferation Assay
Ki-67 immunostaining measures the growth fraction of a cell population by detecting Ki-67, a nuclear antigen present in proliferating cells and absent in quiescent G0 cells. The readout is the percentage of Ki-67-positive nuclei among total counted cells, commonly called the Ki-67 labeling index or proliferation index.
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
LPS-Induced Endotoxemia/Systemic Inflammation
Lipopolysaccharide (LPS)-induced endotoxemia is a widely used in vivo model of acute systemic inflammation in which LPS, a Gram-negative bacterial endotoxin, activates innate immune signaling primarily through TLR4, leading to rapid and transient induction of pro-inflammatory cytokines such as TNF-α, IL-6, and IL-1β in circulation and tissues. This cytokine surge is commonly used as a measurable readout of systemic inflammatory activation and immune dysregulation, and is typically assessed within hours after intraperitoneal LPS administration in mouse models of endotoxemia. The model captures key features of systemic inflammatory response syndrome, including cytokine release, immune cell activation, and downstream tissue responses, and has been used to evaluate anti-inflammatory interventions such as cytokine modulation, lipid mediators, and immune cell-targeting therapies.
-
PCNA Immunodetection Proliferation Assay
PCNA immunodetection measures proliferative activity by detecting proliferating cell nuclear antigen, a nuclear protein associated with DNA polymerase δ function and DNA replication. The assay readout is the proportion of PCNA-positive nuclei among total counted cells, but PCNA labeling is not identical to BrdU labeling because PCNA can mark late G1/early S-associated replication competence and may persist beyond active DNA synthesis depending on fixation and extraction conditions.
-
Imiquimod-Induced Psoriasiform Dermatitis
Imiquimod (IMQ)-induced psoriasiform dermatitis is a widely used murine model in which topical application of IMQ, a Toll-like receptor 7 (TLR7) agonist, triggers innate immune activation in the skin and induces a psoriasis-like inflammatory cascade characterized by epidermal hyperplasia, immune cell infiltration, and cytokine production dominated by the IL-23/IL-17 axis. This inflammatory response is mediated through activation of dendritic cells and downstream induction of IL-23, IL-17A, IL-22, and related pro-inflammatory mediators, recapitulating key features of human plaque psoriasis and enabling mechanistic and therapeutic studies. The model is commonly induced using Aldara (5% IMQ cream) applied topically to murine skin, resulting in rapid onset of erythema, scaling, and thickening that can be quantified as disease severity indices and validated histologically.
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
-
Pyroptosis Solutions
Pyroptosis is a lytic inflammatory cell-death pathway executed by gasdermin pores, most classically through inflammasome-mediated activation of caspase-1, cleavage of gasdermin D, membrane pore formation, LDH release, and secretion of IL-1β and IL-18. The canonical pathway is commonly modeled by priming cells with an inflammatory signal such as LPS to induce pro-IL-1β and inflammasome components, followed by an activation signal such as ATP or nigericin to activate NLRP3, ASC speck formation, caspase-1 cleavage, GSDMD cleavage, cytokine release, and pyroptotic membrane rupture. The non-canonical pathway is triggered when cytosolic LPS activates mouse caspase-11 or human caspase-4/5, leading to GSDMD cleavage and pyroptosis, and this can secondarily activate NLRP3-dependent IL-1β release. Pyroptosis is linked to inflammatory injury, infection, cancer, liver disease, ocular disease, placental inflammation, and other disease phenotypes, but unresolved questions include which gasdermin fam
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Keywords
- PI3K/AKT/JAK2-IN-1
- PI3K
- Akt
- JAK
- TNF Receptor
- Interleukin Related
- PI3K/AKT/JAK2 signaling pathway
- PI3K inhibitor
- AKT inhibitor
- JAK2 inhibitor
- anti-inflammation
- anti-psoriasis
- psoriasis
- biscoumarin derivative
- RAW264.7
- HaCaT
- LPS
- IMQ-induced psoriasis mouse model
- IL-6
- TNF-α
- IL-1β
- IL-17A
- IL-22
- IL-23
- IFN-γ
- NO
- Ki67
- PCNA
- Inhibitor
- inhibitor
- inhibit